TOPLINE:
Compared with chemotherapy alone, the addition of radiation to chemotherapy did not improve overall or recurrence-free survival in patients with locally advanced endometrial cancer, a new phase 3 trial finds.
METHODOLOGY:
- Radiotherapy and, more recently, chemotherapy are used to treat patients with stage III endometrial cancer; however, it remains unclear whether combining the two approaches improves survival outcomes.
- To find out, researchers performed a randomized phase 3 trial in which 813 patients with stage III or IVA endometrial cancer (median age, 60 years) were randomly assigned to receive either chemoradiotherapy (n = 407) or chemotherapy alone (n = 406); of these, 680 received the trial intervention (333 for chemoradiotherapy and 347 for chemotherapy).
- Participants were predominantly non-Hispanic or White individuals, and 10% were Black individuals ; 97% had stage III disease.
- The primary outcome of the trial was recurrence-free survival. The analysis also compared the overall survival for both treatment arms.
TAKEAWAY:
- Patients in the chemoradiotherapy did not demonstrate improved local recurrence rates compared with those in the chemotherapy arm.
- Overall survival was also similar in both groups (stratified hazard ratio for death comparing chemoradiotherapy with chemotherapy, 1.05; 95% CI, 0.82-1.34; P = .72).
- After a median follow-up of 112 months, the median overall survival was not reached in either arm.
- A subgroup analysis found that no factors predicted an overall survival benefit with chemoradiotherapy.
IN PRACTICE:
This updated analysis demonstrated no recurrence-free or overall survival benefit from adding pelvic radiation to chemotherapy in stage III locally advanced endometrial cancer, the authors concluded. The analysis also did not identify any pathologic or demographic factors predictive of a survival benefit in the chemoradiotherapy arm.
SOURCE:
The study, led by Daniela E. Matei, MD, Northwestern University, Chicago, was published online in the Journal of Clinical Oncology.
LIMITATIONS:
The long follow-up duration may have introduced biases related to patient dropout or changes in treatment standards over time. The sample size may not have been sufficient to detect differences in outcomes for specific subgroups, which could have limited the ability to draw definitive conclusions.
DISCLOSURES:
This study was supported by the National Cancer Institute (NCI) awards to the Gynecologic Oncology Group (GOG) Administrative Office, the GOG Statistical Office, NRG Oncology Statistical and Data Management Center, NRG Operations, and NCI Community Oncology Research Program. Several authors reported receiving honoraria and research funding and having other ties with various sources.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Source link : https://www.medscape.com/viewarticle/does-chemoradiotherapy-boost-survival-endometrial-cancer-2025a10001d7?src=rss
Author :
Publish date : 2025-01-21 09:44:35
Copyright for syndicated content belongs to the linked Source.